Adelaide-based Vaxine Pty Ltd, the rapidly growing Australian biotechnology company, has secured $15.0M in a Series C funding round to advance its impressive pipeline of vaccines. The company is focused on developing solutions against infectious disease, allergy, and cancer.
At the heart of Vaxine's work is its proprietary Advax range of polysaccharide adjuvants. This state-of-the-art technology is currently being applied to develop vaccines against a wide array of global health challenges, including hepatitis B, pandemic influenza, Japanese encephalitis, West Nile virus, malaria, HIV, and rabies.
.png&w=3840&q=75)
.png&w=3840&q=75)
.png&w=3840&q=75)
